12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga_article·11 hours agoAMLX+63.84%ALPS-7.68%
BioVie FY26 net loss widens to $22.1 million; operating expenses rise to $22.7 millionPUBT·Aug 13 at 05:05 AMBIVI-17.57%
Biotech Stocks At 52-Week Highs - BIVI +22%, XNCR, ANRO, HAE, ACADrttnews·Aug 13 at 03:30 AMANRO+1.58%ACAD+4.03%
BIVI: Bezisterim phase II data show significant motor and non-motor benefits and slowed neurodegenerationQuartr·Aug 12 at 05:50 PMBIVI-17.57%
BIVI: Bezisterim showed significant clinical and biomarker benefits in early Parkinson's, supporting Phase 3Quartr·Aug 12 at 02:45 PMBIVI-17.57%
12 Industrials Stocks Moving In Wednesday's Intraday Sessionbenzinga_article·Aug 12 at 12:05 PMATRO-7.45%ELOG+2.30%
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga_article·Aug 7 at 12:05 PMCVRX0.00%EMBC-0.58%
Join Biovie's Exclusive Live Investor Webinar: Inside the SUNRISE-PD Topline ResultsMorningStar·Aug 7 at 08:09 AMBIVI-17.57%
BioVie posts corporate presentation outlining bezisterim, BIV201 clinical programs in neurodegeneration, Long COVID, liver diseasePUBT·Aug 7 at 05:39 AMBIVI-17.57%
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga_article·Aug 6 at 12:06 PMBLLN-6.30%CELZ-1.82%
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga_article·Aug 6 at 07:06 AMCNTX-6.37%ENSC+2.23%
BioVie posts corporate presentation outlining bezisterim and BIV201 clinical programsPUBT·Aug 6 at 06:59 AMBIVI-17.57%
BioVie says Phase 2 SUNRISE-PD trial shows bezisterim improves motor and non-motor symptoms in early Parkinson’s diseasePUBT·Aug 6 at 06:36 AMBIVI-17.57%
U.S. stock market midday update: Biovie up 9.62% on increased volume, no major positive drivers, intensified capital speculationPrice Alert·Aug 5 at 12:53 PMBIVI-17.57%
